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Abstract
Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor which has been
used in conjunction with other anti-cancer agents in the treatment of patients with many cancers. It remains controversial
whether bevacizumab can prolong survival in cancer patients. This meta-analysis was therefore performed to evaluate effect
of bevacizumab on survival in cancer patients. PubMed, EMBASE, and Web of Science databases were searched for English-
language studies of randomized controlled trials comparing bevacizumab with control therapy published through February
8, 2012. Progression-free survival, overall survival, and one-year survival rate were analyzed using random- or fixed-effects
model. Thirty one assessable randomized controlled trials were identified. A significant improvement in progression-free
survival in cancer patients was attributable to bevacizumab compared with control therapy (hazard ratio, 0.72; 95%
confidence interval, 0.68 to 0.76; p,0.001). Overall survival was also significantly longer in patients were treated with
bevacizumab (hazard ratio, 0.87; 95% confidence interval, 0.83 to 0.91; p,0.001). The significant benefit in one-year survival
rate was further seen in cancer patients receiving bevacizumab (odds ratio, 1.30; 95% confidence interval, 1.20 to 1.41;
p,0.001). Current evidences showed that bevacizumab prolong progression-free survival and overall survival, and increase
one-year survival rate in cancer patients as compared with control therapy.
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Introduction
Angiogenesis is a universal requirement for the growth of solid
tumors beyond the limits of oxygen diffusion from the existing
vasculature, and plays a crucial role in the growth and metastasis
of cancer [1]. Vascular endothelial growth factor (VEGF), a key
mediator of angiogenesis, is overexpressed in many tumor types,
and has been associated with poor prognosis [1,2]. The
experimental in vivo inhibition of the VEGF pathway results in
tumor growth inhibition and improves delivery of chemothera-
peutic drugs by reducing tumor interstitial fluid pressure and by
changing vessel diameter, density, and permeability in response to
treatment [3]. These data prompted the clinical investigation of
bevacizumab (Avastin; Genentech, South San Francisco, CA), a
humanized anti-VEGF monoclonal IgG1 antibody in the treat-
ment of cancer patients.
Bevacizumab has shown benefits in the treatment of many types
of malignancy including colorectal cancer, non–small cell lung
cancer, renal cell carcinoma, breast cancer, and glioblastoma [4].
Bevacizumab monotherapy has been notably less studied in cancer
patients than bevacizumab combined with chemotherapy, and
fatal adverse events have been reported in cancer patients treated
with bevacizumab in combination with chemotherapy [5]. In a
recent meta-analysis, Ranpura et al [6] have reported that
bevacizumab in combination with chemotherapy or biological
therapy was associated with increased treatment-related mortality
as compared with chemotherapy alone. To better understand the
overall impact of bevacizumab on survival of patients with cancer,
we conducted a systematic review and meta-analysis of published
randomized controlled trials (RCTs) to evaluate the effect of
bevacizumab on progression-free survival (PFS), overall survival
(OS), and one-year survival rate (OYSR) in patients with cancer.
Methods
Data sources and searches
Two investigators searched PubMed, EMBASE, and Web of
Science databases for relevant articles published until February 8,
2012; no lower date limit was applied. We used the following
Medical Subject Heading terms and keywords: ‘‘bevacizumab’’,
‘‘Avastin’’, and ‘‘carcinoma/cancer’’, and the searches were
limited initially to English publications of RCTs in humans. The
search strategy also used text terms such as ‘‘progression-free
survival’’, ‘‘overall survival’’, ‘‘one-year survival rate’’ and
‘‘vascular endothelial growth factor’’ to identify relevant informa-
tion. We screened the reference lists of included studies and related
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trials. Results were double-checked and arbitrated by a second
investigator.
Study selection
We included full-text publications that investigated patients with
cancer during treatment with bevacizumab compared with
placebo, or bevacizumab-containing chemotherapy regimen with
the same regimen either without bevacizumab or with bevacizu-
mab replaced by a placebo, or with different doses of
bevacizumab. We excluded studies that were not published as
full reports, such as conference abstracts and letters to editors.
Data extraction and quality assessment
To avoid bias in the data-abstraction process, 2 investigators
independently abstracted the data from the trials and subsequently
compared the results. The following information was obtained
from each report: the first author, the year of publication, the
period and location of study, and the numbers of patients enrolled,
randomized and analyzed, the proportion of patients who were
men, the therapy regimen, the duration of follow up, hazard ratios
(HRs) for PFS and OS, and odds ratios (ORs) for OYSR
comparing bevacizumab-based therapies with control arms. When
studies compared 2 or more doses of bevacizumab with a control,
we used data from the group with the highest dose. All data were
checked for internal consistency, and disagreements were resolved
by discussion among the investigators.
Quality assessment of the publications included was done
unblinded by three investigators using a 10 point scoring system as
described in a previous meta-analysis [7].
Statistical analysis
If HRs for PFS or/and OS were not reported in the original
publications, we calculated HR values and their 95% confidence
intervals (CIs) in each RCT using the abstracted survival
probabilities in the Kaplan-Meier curve at specific time points
according to the methods proposed by Parmar et al [8]. Minimum
and maximum follow-up times were used to estimate censored
subjects under the assumption that censoring happens constantly
throughout follow-up. If the minimum follow-up time was not
available, time zero was substituted for it. HRs were calculated to
show how many times higher the probability of death from any
cause in patients receiving bevacizumab as compared with those
receiving control therapies.
We calculated ORs to assess OYSR advantage of bevacizumab
as compared with control therapy. We constructed 262 tables
from abstracted data for OYSR. ORs and their 95% CIs for the
subjects who received bevacizumab relative to those receiving
control therapy were calculated from the tables. For OR
calculations we excluded ineligible subjects from each evaluation.
A general variance-based method was used to estimate the
summary HRs, ORs, and their 95% CIs. We assessed heteroge-
neity between studies with the I
2 statistic [9] as a measure of the
proportion of total variation in estimates that is due to
heterogeneity, where I
2 value of 50% correspond to cut-off point
for a significant heterogeneity. Based on the statistical significance
of heterogeneity test, we applied a random-effects model or fixed-
effects model to perform meta-analyses. We also used Egger’s test
[10] to detect possible publication bias.
All statistical analyses were conducted with Comprehensive
Meta-Analysis version 2.2.055 software (Englewood, NJ, USA).
Results
Eligible RCTs
After independent review, seventy-nine publications [11–89]
reporting RCT results with bevacizumab in patients with various
cancers were considered to be eligible for inclusion in the analysis
(Figure 1). Of 79 publications, 11 were excluded because the same
authors published several reports on the same patients, and only
the best-quality study was considered [41–51], 18 were excluded
because they did not provide acquired data for calculating HR and
OR values [52–69], 20 were excluded because they did not
include suitable control groups [70–89]. Subsequently, 30
publications [11–40] were available for analyzing the effect of
bevacizumab on survival in patients with cancer.
Study characteristics and quality
Baseline characteristics of the 31 RCTs included in the present
meta-analysis are listed in Table S1. These RCTs include 10 phase
2 and 21 phase 3 studies, and they were all published since 2003.
Eleven RCTs were from USA, 1 from Germany, 1 from Greece,
the remaining 18 from multiple countries (more than 3 countries,
including Europe and USA). We noted that the mean of quality
scores was 7.6, with a range between 5 and 10 (Table S1).
Therefore, the overall quality of all trials was quite good.
Survival in overall population
The meta-analysis of PFS was based on 29 publications with 30
RCT s [11–23,25–30,31–40], involving 18,132 cancer patients. A
statistically significant improvement in PFS was observed favoring
bevacizumab groups compared with control groups (pooled HR,
0.72; 95% CI, 0.68 to 0.76; p,0.001; random-effects model)
(Figure 2). Overall test for heterogeneity showed that I
2=51.30
(p,0.001), indicating a significant heterogeneity between studies.
Evaluation of publication bias showed that the Egger test was not
significant (p=0.669). The funnel plots for publication bias also
showed an apparent symmetry (data not shown). These results
indicated that there was no publication bias.
The meta-analysis of OS was based on 27 publications with 28
RCTs [11–13,15–30,32–33,35–40], involving 16,462 cancer
patients. Bevacizumab had improvement in OS as compared
with control therapy (HR, 0.87; 95% CI, 0.83 to 0.91; p,0.001;
fixed-effects model) (Figure 3). Overall test for heterogeneity
showed that I
2=1.11 (p=0.448), indicating no heterogeneity
between studies. We recorded no evidence of publication bias with
the Egger test (p=0.540).
The OR values of OYSR for meta-analysis were available or
have been computed from 24 publications with 25 RCTs [11–
13,16–24,26–30,32,33,35,36,38–40]. The analysis showed signif-
icant improvement in OYSR for bevacizumab versus control
(OR=1.30; 95% CI, 1.20 to 1.41; p,0.001; fixed-effects model)
(Figure 4). Overall test for heterogeneity showed that I
2=15.03
(p=0.250), indicating no heterogeneity between studies. We
recorded no evidence of publication bias with the Egger test
(p=0.559).
Bevacizumab monotherapy was administered in only one RCT
[32], in the remaining 30 RCTs, bevacizumab was combined with
chemotherapy. After excluding the RCT with bevacizumab
monotherapy, HRs of PFS and OS with bevacizumab remained
similar and was 0.72 (95% CI, 0.67 to 0.76; p,0.001) and 0.87
(95% CI, 0.83 to 0.91; p,0.001), respectively; OR of OYSR also
remained similar and was 1.30 (95% CI, 1.20 to 1.42; p,0.001).
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Based on the statistical significance of heterogeneity test, a
random-effects model or fixed-effects model was used to alalyze
the effects of bevacizumab on survival in patients with cancers in
following subgroups.
From 7 RCTs with lung cancer [11–17], 7 with colorectal
cancer [18–23,25], 7 with breast cancer [26–30,31], 3 with renal
cell carcinoma [32–34], 2 with pancreatic cancer [35,36], 2 with
ovarian cancer [37,38], and 2 with the other cancers (liver cancer
and gastric cancer) [39,40], data could be obtained for analyzing
PFS. Our data showed that bevacizumab was associated with
significant improvement in PFS in patients with all kinds of
cancers, except for liver cancer and gastric cancer (Table S2).
From 6 RCTs with lung cancer [11–13,15–17], 8 with colorectal
cancer [18–25], 6 with breast cancer [26–30(1, 2)], 2 with renal
cell carcinoma [32–33], and 2 with pancreatic cancer [35,36], 2
with ovarian cancer [37–38],1 liver cancer and 1 gastric cancer
[39,40], data could be obtained for analyzing OS. From 5 RCTs
with lung cancer [11–13,16–17], 7 with colorectal cancer [18–24],
6 with breast cancer [26–30(1, 2)], 2 with renal cell carcinoma
[32–33], and 2 with pancreatic cancer [35,36], 1 with ovarian
cancer [38], 1 liver cancer and 1 gastric cancer [39,40], data could
be obtained for analyzing OYSR. Also as shown in Table S2,
bevacizumab improved OS in patients with lung cancer and
colorectal cancer, but not with renal cell carcinoma, breast cancer,
pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.
It was found that bevacizumab had benefit in improvement of
OYSR in patients with colorectal cancer, breast cancer and
ovarian cancer, but not with lung cancer, renal cell carcinoma,
pancreatic cancer, liver cancer and gastric cancer.
From 22 RCTs [11–17,20,22,26–30,31–34,36–37,39] of bev-
acizumab at an equivalent of 5.0 mg/kg per week or more (high
dose) and 12 RCTs [11,14,18–19,21,23,25,28,32,35,38,40] of
bevacizumab at 2.5 mg/kg per week (low dose), data could be
obtained for analyzing PFS. From 19 RCTs [11–13,15–
17,20,22,26–30,32–33,36–37,39] of high-dose bevacizumab and
12 RCTs [11,18–19,21,23–25,28,32,35,38,40] of low dose bev-
acizumab, data could be obtained for analyzing OS. From 17
RCTs [11–13,16–17,20,22,26–30,32–33,36,39] of high-dose bev-
acizumab and 11 RCTs [11,18–19,21,23–24,28,32,35,38,40] of
low dose bevacizumab, data could be obtained for analyzing
OYSR. Our analysis revealed that the cancer patients treated with
both high and low doses of bevacizumab showed better PFS and
OS benefits compared with those treated with control therapies
(Table S2). Similar to PFS and OS results, the cancer patients
treated with both high and low doses of bevacizumab also showed
a better benefit on OYSR compared with those treated with
control therapies (Table S2). Overall, no statistically significant
difference was found for the effect of bevacizumab on PFS, OS
and OYSR between the high and low doses of bevacizumab (all
p.0.05).
To determine whether the type of chemotherapeutic agent may
alter the impact of bevacizumab on patients’ survival, we
performed a subgroup analysis stratified according to drug class
such as platinum (cisplatin, carboplatin, or oxaliplatin) and taxanes
(paclitaxel or docetaxel) [11–15,17,20–21,27–30,31,37–38,40]
versus others (nonplatinum- and nontaxane-based chemotherapies
Figure 1. A flow chart showing the progress of trials through the review.
doi:10.1371/journal.pone.0035629.g001
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26,30,33–36,39]. Also shown in Table S2, the HR values of PFS
and OS, and the OR value of OYSR for bevacizumab with
platinum- or taxane-containing regimens were similar to those for
nonplatinum- or nontaxane-based regimens. This difference in risk
of PFS, OS and OYSR with bevacizumab among these
chemotherapeutic classes was not statistically significant (all
p.0.05).
Discussion
Most cancers are diagnosed with unresectable advanced disease
[90]. Systemic chemotherapy or radiotherapy is indicated for the
cancer patients with advanced disease to prolong survival, control
symptoms and maintain or improve quality of life. However, the
benefit of chemoradiotherapy is counterbalanced by increased and
prohibitive toxicity, particularly among cancer patients with
coexisting medical conditions and decreased performance status.
Therefore, novel therapeutic strategies are needed. Bevacizumab
can bind selectively circulating VEGF, and thus inhibits the
binding of VEGF to its cell surface receptors. This inhibition leads
to a reduction in microvascular growth of tumor blood vessels and
thus limits the blood supply to tumor tissues [91]. As a matter of
fact, bevacizumab has been used in conjunction with other anti-
cancer agents in the treatment of patients with many cancers.
Recently, several meta-analyses revealed that the use of
bevacizumab was associated with increased risks of arterial
thromboembolism [92], venous thromboembolism [93], gastroin-
testinal perforation [94], severe proteinuria [95], and high-grade
hypertension [96], and treatment-related mortality [6]. Although
the inhibition of VEGF by bevacizumab has been noted to cause
serious adverse events, evidence has continued to accumulate that
bevacizumab is a powerful anti-angiogenic agent that has efficacy
in the treatment of a wide variety of cancers. The present meta-
analysis has shown the benefit of bevacizumab in the treatment of
patients with cancer. A significant improvement in PFS, OS and
OYSR was seen in overall population with cancer receiving
bevacizumab-based therapies when compared with control
therapies.
We failed to perform the meta-regression analysis to assess the
effect of bevacizumab monotherapy or combination with chemo-
therapy on cancer patients’ survival, since bevacizumab mono-
therapy was studied in only one RCT [32]. After excluding the
RCT with bevacizumab monotherapy, HRs of PFS and OS with
bevacizumab remained similar and were all significant improved.
Therefore, according to the results of the present meta-analysis,
the addition of bevacizumab to first-line chemotherapy regimens
would provide a significant advantage in terms of PFS, OS, and
OYSR.
We evaluated impact of bevacizumab on cancer patients’
survival according to tumor type, and noted that bevacizumab
improved in PFS in patients with most of cancers studied except
for liver cancer and gastric cancer, but did not improve OS in
patients with renal cell carcinoma, breast cancer, pancreatic
cancer, ovarian cancer, liver cancer and gastric cancer, did not
improved OYSR in patients with lung cancer, renal cell
carcinoma pancreatic cancer, ovarian cancer, liver cancer and
gastric cancer. These data suggested that patients with some kinds
of cancers, such as lung cancer and colorectal cancer, would
obtain more survival benefit from bevacizumab therapy compared
with the other kinds.
Our subgroup analysis revealed that the cancer patients treated
with both high and low doses of bevacizumab showed better PFS,
OS, and OYSR benefits compared with those treated with control
therapies. Overall, no statistically significant difference was found
for the effect of bevacizumab on PFS, OS and OYSR between the
high and low doses of bevacizumab. These data suggested that
cancer patients treated with higher dose of bevacizumab did not
have more favorable benefit in PFS, OS, as well as OYSR than
those treated with lower dose. Since lower dose were as effective as
higher doses, and higher dose is associated with significantly
increased risk with serious adverse events [6], and thus should be
the recommended for patients with cancer in case of need.
Although the primary aim of the present meta-analysis was to to
evaluate effect of bevacizumab on survival in cancer patients, one
should also pay attention to the adverse events risk associated with
bevacizumab. Recent meta-analyses have shown that bevacizu-
mab could increase the risk of left ventricular dysfunction and
hemorrhagic events, and even were associated with fatal adverse
events, including treatment-related mortality [6,97]. The interac-
tion between bevacizumab and certain chemotherapeutic agents
might also affect the effects of bevacizumab on cancer patients’
survival. However, our further subgroup analysis showed HR
values of PFS and OS, and the OR values of OYSR for
bevacizumab with platinum- or taxane-containing regimens were
Figure 2. Meta-analysis of the hazard ratios of progression-free
survival between bevacizumab and control therapy using
random effect model. Bars, 95% confidence intervals (CI) of
hazard ratio in patients receiving bevacizumab versus con-
trols. The areas of the squares are proportional to the weights used for
combining the data. The center of the lozenge gives the combined
hazard ratio. The hazard ratio was considered statistically significant if
the 95% CI for the overall hazard ratio did not overlap one.
doi:10.1371/journal.pone.0035629.g002
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The difference in risk of PFS, OS and OYSR with bevacizumab
among these chemotherapeutic classes was not statistically
significant.
Several technical issues have to be mentioned in relation to this
meta-analysis. This meta-analysis was not based on individual
patient data and was not subjected to an open external evaluation
procedure. Meta-analyses based on published data tend to
overestimate treatment effects compared with individual patient
data analyses. However, analyses using individual patient data
may include fewer studies if all authors do not agree to submit
their full databases to the analyzing group. Another drawback of
analyses based on individual patient data is the time-consuming
review process. The results must therefore be interpreted
cautiously, as an individual patient data-based meta-analysis
would give more reliable estimation than one based on abstracted
data [98]. Publication bias is a significant threat to the validity of
the results, however, such a situation did not exist in the present
meta-analysis. Heterogeneity among trials may be another
limitation of our meta-analysis, even though we applied a
random-effects model that takes possible heterogeneity into
consideration. The accuracy of the values of HR and OR
estimated from the Kaplan-Meier curves is another important
issue. We obtained fairly good correlation between the HRs and
ORs reported in this article and those obtained based on the
Kaplan-Meier curves, suggesting that curve-based HRs or/and
ORs can be substituted in cases where the HRs or/and ORs are
not available.
Figure 3. Meta-analysis of the hazard ratios of overall survival between bevacizumab and control therapy using random effect
model. Bars, 95% confidence intervals (CI) of hazard ratio in patients receiving bevacizumab versus controls. The areas of the squares are
proportional to the weights used for combining the data. The center of the lozenge gives the combined hazard ratio. The hazard ratio was
considered statistically significant if the 95% CI for the overall hazard ratio did not overlap one.
doi:10.1371/journal.pone.0035629.g003
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well as OYSR was significantly improved in cancer patients
treated with bevacizumab as compared with control therapies.
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